Seed funding round finalised

EpiHeart is dedicated to enable new treatments that improve long term survival and quality of life of cardiac patients.  Our initial focus is in Cardiac Micrograft Therapy(TM). During  Cardiac Artery Bypass Grafting (CABG) surgery patient's own cardiac tissue is processed into micrografts, cleaned and transplanted back to support cardiac tissue regeneration. The pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size - critical factors contributing to heart failure. 

EpiHeart is a University spin-off company leveraging over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we continue  collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University. 

EpiHeart is open for collaboration. We foresee collaboration possibilites in following areas:

• Clinical studies with European and US clinics performing CABG surgeries. 
• Distributors able to serve and interact clinics performing CABG surgeries.
• Research and commercial collaboration relating advanced therapies (cell and gene therapies) that could be administered surgically   

Feel free to request further information on our science, clinical trial program and more.